相关实验视频

Updated: May 2, 2026

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.0K

美国食品和药物管理局 (FDA) 拒绝阿勒姆图祖马布,导致神经病学家分歧

Asher Mullard

    Lancet (London, England)
    |March 12, 2014
    PubMed
    概括

    No abstract available in PubMed .

    更多相关视频

    Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
    06:15

    Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

    Published on: October 27, 2014

    29.3K
    Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells
    12:52

    Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells

    Published on: November 28, 2015

    15.6K

    相关实验视频

    Last Updated: May 2, 2026

    Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
    09:34

    Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

    Published on: February 17, 2022

    3.0K
    Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
    06:15

    Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

    Published on: October 27, 2014

    29.3K
    Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells
    12:52

    Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells

    Published on: November 28, 2015

    15.6K

    相关概念视频

    Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

    Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

    97
    PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
    97
    JoVE
    关于 JoVE
    概览领导团队博客JoVE 帮助中心
    作者
    出版流程编辑委员会范围与政策同行评审常见问题投稿
    图书馆员
    用户评价订阅访问资源图书馆顾问委员会常见问题
    研究
    JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
    教育
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
    使用条款与条件
    隐私政策
    政策
    Jove
    Visualize
    联系我们